Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Want to see ATAI full AI Analyst Report?
Top Page
Atai Beckley N.V.
(NASDAQ:ATAI)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.50
▲(36.48% Upside)
Action:Reiterated
Date:06/27/26
Overall score reflects weak financial performance driven by minimal revenue scale, large losses, and significant ongoing cash burn, partially offset by low leverage and a still-meaningful equity base. Technicals are supportive with price above major moving averages and positive MACD, but momentum appears stretched (high RSI), and valuation inputs are not very informative due to negative earnings and no dividend data.
Positive Factors
Low leverage and sizable equity base
Very low leverage and a meaningful equity cushion provide durable financial flexibility to support multi-year clinical programs. This reduces near-term solvency risk, enables strategic R&D funding or partnerships without immediate distress, and lengthens runway versus peers reliant on debt.
Negative Factors
Large and persistent cash burn
Sustained negative operating and free cash flow indicates the business requires external financing to sustain R&D and operations. Persistent burn raises dilution risk, limits strategic optionality, and places pressure on management to secure partnerships or equity raises within the next 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and sizable equity base
Very low leverage and a meaningful equity cushion provide durable financial flexibility to support multi-year clinical programs. This reduces near-term solvency risk, enables strategic R&D funding or partnerships without immediate distress, and lengthens runway versus peers reliant on debt.
Read all positive factors
Atai Beckley N.V. (ATAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.95B
Dividend YieldN/A
Average Volume (3M)5.04M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees99
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.00
Shares Outstanding368,166,700
10 Day Avg. Volume5,663,783
30 Day Avg. Volume5,044,463
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue417.81
Enterprise Value/Gross Profit509.38
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$16.71Price Target Upside314.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$1.26M
Atai Beckley N.V. Business Overview & Revenue Model
Company Description
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend acr...
How the Company Makes Money
ATAI is a clinical-stage company and, as such, it does not primarily generate recurring revenue from commercialized products. Its potential and historical sources of cash inflow are typically tied to its drug-development platform: (1) partnering a...
Atai Beckley N.V. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.49M | 4.09M | 308.00K | 314.00K | 233.00K | 20.38M |
| Gross Profit | 2.86M | 3.08M | -165.00K | -5.00K | 65.00K | 20.33M |
| EBITDA | -662.49M | -657.67M | -147.33M | -39.90M | -150.10M | -178.19M |
| Net Income | -663.40M | -660.05M | -149.27M | -40.22M | -152.38M | -167.81M |
Balance Sheet | ||||||
| Total Assets | 264.88M | 310.54M | 159.39M | 293.48M | 305.44M | 414.17M |
| Cash, Cash Equivalents and Short-Term Investments | 230.77M | 256.04M | 62.33M | 179.26M | 273.11M | 362.27M |
| Total Debt | 2.00M | 2.07M | 24.71M | 19.14M | 15.34M | 743.00K |
| Total Liabilities | 66.10M | 88.54M | 42.83M | 49.16M | 39.67M | 28.21M |
| Stockholders Equity | 198.68M | 221.87M | 116.30M | 242.96M | 260.74M | 376.91M |
Cash Flow | ||||||
| Free Cash Flow | -117.19M | -103.58M | -82.53M | -84.71M | -105.49M | -64.37M |
| Operating Cash Flow | -106.60M | -102.67M | -82.44M | -84.12M | -104.47M | -63.25M |
| Investing Cash Flow | -120.02M | -109.13M | 59.17M | -53.30M | -86.85M | -81.28M |
| Financing Cash Flow | 213.28M | 269.48M | 5.37M | -8.36M | 20.79M | 409.86M |
Atai Beckley N.V. Technical Analysis
Positive
4.03
Price Trends
4.25
Positive
3.99
Positive
4.28
Positive
Market Momentum
0.10
Negative
73.55
Negative
83.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATAI, the sentiment is Positive. The current price of 4.03 is below the 20-day moving average (MA) of 4.23, below the 50-day MA of 4.25, and below the 200-day MA of 4.28, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 73.55 is Negative, neither overbought nor oversold. The STOCH value of 83.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATAI.
Atai Beckley N.V. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $9.14B | -24.48 | -43.02% | ― | -100.00% | -24.90% | |
55 Neutral | $1.12B | -5.50 | -56.41% | ― | -31.58% | -27.41% | |
52 Neutral | $1.95B | -1.76 | -366.49% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.15B | -7.56 | -87.00% | ― | -36.24% | 11.52% | |
49 Neutral | $986.52M | -6.62 | -35.33% | ― | ― | 23.91% |
* Healthcare Sector Average
ATAI
Atai Beckley N.V.
5.29
3.09
140.45%
NKTR
Nektar Therapeutics
63.65
37.89
147.09%
WVE
Wave Life Sciences
5.83
-0.84
-12.59%
ORIC
Oric Pharmaceuticals
9.53
-0.78
-7.57%
PRAX
Praxis Precision Medicines
327.79
284.79
662.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.